Article

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

2017-12-07

Abstract excerpt

Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard therapy for cancer patients with activating BRAF mutations. However, the anti-tumorigenic effect and clinical benefit are only transient, and tumors are prone to treatment resistance and relapse. To elucidate mechanistic insights into drug resistance, we have established an in vitro cellular model of MAPK inhibitor resistance i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8148ded4-40b8-5f23-86a2-a0d0905b2476
DOI: 10.1101/231142

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaDOI 10.1101/231142Read

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read

Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF <sup>V600</sup> melanomaSemantic proximity Read

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance.Semantic proximity Read

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read

Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibitionSemantic proximity Read

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read